Functional validation of genomic alterations in lung cancer. To determine oncogenic drivers of SCLC, we characterize genomic alterations in tumor progression using genetically engineered precancerous cells and mouse models. Our efforts are focused on three areas of interests as follows: 1. To better understand transcriptional program altered by frequent mutations in transcription factors and chromatin modifiers, we integrate functional genetics with omics approach. 2. To delineate signaling pathways for tumor progression and homeostasis, we study roles of developmental and growth factor signaling pathways that are deregulated during tumor development. 3. To determine role of metabolic plasticity in mutant cells during tumor progression, we aim to identify and characterize altered metabolic pathways in tumorigenesis and their relationships to oncogenic drivers.